TWI265809B - Dispersible pharmaceutical composition for treatment of mastitis and otic disorders - Google Patents

Dispersible pharmaceutical composition for treatment of mastitis and otic disorders

Info

Publication number
TWI265809B
TWI265809B TW093107484A TW93107484A TWI265809B TW I265809 B TWI265809 B TW I265809B TW 093107484 A TW093107484 A TW 093107484A TW 93107484 A TW93107484 A TW 93107484A TW I265809 B TWI265809 B TW I265809B
Authority
TW
Taiwan
Prior art keywords
agent
treatment
fluid
pharmaceutical composition
antibacterial agent
Prior art date
Application number
TW093107484A
Other languages
English (en)
Other versions
TW200507852A (en
Inventor
Nancy J Britten
John W Burns
John W Hallberg
Niki A Waldron
Jeffrey L Watts
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of TW200507852A publication Critical patent/TW200507852A/zh
Application granted granted Critical
Publication of TWI265809B publication Critical patent/TWI265809B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
TW093107484A 2003-03-20 2004-03-19 Dispersible pharmaceutical composition for treatment of mastitis and otic disorders TWI265809B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45620103P 2003-03-20 2003-03-20

Publications (2)

Publication Number Publication Date
TW200507852A TW200507852A (en) 2005-03-01
TWI265809B true TWI265809B (en) 2006-11-11

Family

ID=33030090

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093107484A TWI265809B (en) 2003-03-20 2004-03-19 Dispersible pharmaceutical composition for treatment of mastitis and otic disorders

Country Status (19)

Country Link
US (1) US20040214753A1 (zh)
EP (1) EP1608406A1 (zh)
JP (1) JP2006520778A (zh)
KR (1) KR100765614B1 (zh)
CN (1) CN1761486A (zh)
AR (1) AR043651A1 (zh)
AU (1) AU2004222518A1 (zh)
BR (1) BRPI0408559A (zh)
CA (1) CA2519589A1 (zh)
CL (1) CL2004000471A1 (zh)
CO (1) CO5611165A2 (zh)
MX (1) MXPA05010019A (zh)
NO (1) NO20054777L (zh)
NZ (1) NZ541780A (zh)
RU (1) RU2321423C2 (zh)
TW (1) TWI265809B (zh)
UY (1) UY28236A1 (zh)
WO (1) WO2004082719A1 (zh)
ZA (1) ZA200506531B (zh)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020035107A1 (en) * 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
DE10161077A1 (de) * 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
BR0316976A (pt) * 2002-12-02 2005-10-25 Byocoat Entpr Inc Composição e método para tratamento de doença fúngica em planta
MXPA05009507A (es) 2003-03-05 2006-03-10 Byocoat Entpr Inc Solucion y proceso antimicrobianos.
EP1568369A1 (en) * 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
ES2292122T3 (es) * 2004-04-22 2008-03-01 Pfizer Products Incorporated Procedimiento de estabilizacion de sal sodica de cefovecina desordenada.
DE102004021281A1 (de) * 2004-04-29 2005-11-24 Boehringer Ingelheim Vetmedica Gmbh Verwendung von Meloxicam-Formulierungen in der Veterinärmedizin
DE102004030409A1 (de) * 2004-06-23 2006-01-26 Boehringer Ingelheim Vetmedica Gmbh Neue Verwendung von Meloxicam in der Veterinärmedizin
US7618651B2 (en) * 2004-06-24 2009-11-17 Idexx Laboratories Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same
US7854943B2 (en) * 2004-06-24 2010-12-21 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
US7858115B2 (en) 2004-06-24 2010-12-28 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
DE102005055385A1 (de) * 2004-12-09 2006-06-14 Bayer Healthcare Ag Arzneimittel zur hygienischen Applikation im Ohr
AT501376B1 (de) * 2005-01-17 2010-11-15 Pregenzer Bruno Glucokortikoid-hältiges arzneimittel
BRPI0617208A2 (pt) * 2005-09-30 2011-07-19 Boehringer Ingelheim Vetmed preparação farmacêutica contendo meloxicam
US7959943B2 (en) 2006-05-10 2011-06-14 Medtronics Xomed, Inc. Solvating system and sealant for medical use in the middle or inner ear
US20070264296A1 (en) * 2006-05-10 2007-11-15 Myntti Matthew F Biofilm extracellular polysachharide solvating system
US7993675B2 (en) 2006-05-10 2011-08-09 Medtronic Xomed, Inc. Solvating system and sealant for medical use in the sinuses and nasal passages
US7976873B2 (en) 2006-05-10 2011-07-12 Medtronic Xomed, Inc. Extracellular polysaccharide solvating system for treatment of bacterial ear conditions
NZ574396A (en) * 2006-07-10 2012-07-27 Advanced Enzyme Technologies Ltd Compositions for prevention and treatment of mastitis and metritis comprising a combination of serratiopeptidase, lysozymes, oscium sanctum, or azardirecta indica
CA2676081C (en) * 2007-02-08 2015-07-07 Medtronic Xomed, Inc. Solvating system and sealant for medical use
US8088095B2 (en) 2007-02-08 2012-01-03 Medtronic Xomed, Inc. Polymeric sealant for medical use
BRPI0700969A (pt) 2007-03-22 2008-11-04 Ouro Fino Participacoes E Empr composição para o tratamento de afecções bacterianas e inflamatórias em animais de companhia
US20100298386A1 (en) * 2007-10-03 2010-11-25 Burwell Steven R Compositions and methods for treating mastitis
CA2727432C (en) 2008-06-12 2016-10-11 Medtronic Xomed, Inc. Method for treating chronic wounds with an extracellular polymeric substance solvating system
US8318817B2 (en) * 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
EP2346324A4 (en) 2008-10-06 2012-10-10 Microbial Defense Systems Llc ANTIMICROBIAL COMPOSITION AND METHODS OF MAKING AND USING
CN101953784B (zh) * 2009-07-16 2012-02-08 中国农业大学 含阿莫西林、硫酸粘菌素和泼尼松龙的兽用混悬液及其制备方法
WO2011046853A1 (en) * 2009-10-12 2011-04-21 Boehringer Ingelheim Vetmedica Gmbh Containers for compositions comprising meloxicam
SG183846A1 (en) 2010-03-03 2012-10-30 Boehringer Ingelheim Vetmed Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
EP3456200B1 (en) 2011-05-10 2023-05-03 Next Science IP Holdings Pty Ltd Article having an antimicrobial solid and use thereof
BRPI1103782A2 (pt) * 2011-08-19 2013-07-30 Eurofarma Lab Ltda produto veterinÁrio para tratamento de mastite, pre composiÇço antibiàtica a anti inflamatària, kit, mÉtodo de preparaÇço uso e mÉtodo de tratamento de mastite
CN102784161A (zh) * 2012-08-01 2012-11-21 张吉川 一种治疗急慢性中耳炎的特效滴耳液
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
CN104825474B (zh) * 2015-04-30 2018-02-06 中国农业科学院兰州畜牧与兽药研究所 一种治疗动物体表损伤的药物组方及其制备工艺
RU2693041C2 (ru) * 2015-05-06 2019-07-01 ЗОИТИС СЕРВИСЕЗ ЭлЭлСи Состав гидрогеля с умеренной адгезией
US10434097B1 (en) 2015-09-14 2019-10-08 Gateway Biotechnology, Inc. Methods and compositions for treating hearing disorders
TW202247855A (zh) 2016-09-13 2022-12-16 美商愛力根公司 非蛋白梭菌毒素組成物
CN107252441A (zh) * 2017-08-07 2017-10-17 咸阳职业技术学院 一种治疗奶牛乳腺炎的药物组合物及其制备方法
WO2019126783A1 (en) * 2017-12-22 2019-06-27 Otonomy, Inc. Triglyceride otic formulations and uses thereof
CA3132159C (en) * 2019-03-06 2023-11-21 Zoetis Services Llc A ready-to-use injectable formulation comprising cefovecin
AU2020337084A1 (en) * 2019-08-27 2022-04-07 Kashiv Biosciences, Llc Compounds useful to treat pain

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3636194A (en) * 1969-10-23 1972-01-18 Douglas G Parizeau Composition and method for treating mastitis with therapeutic agents
DE2063896A1 (de) * 1970-12-28 1972-07-20 Dynamit Nobel Ag, 5210 Troisdorf Salbengrundlagen auf der Basis von Triglyceriden gesättigter mittelkettiger Fettsäuren und Verfahren zu deren Herstellung
ES2079994B1 (es) * 1992-10-07 1996-08-01 Cusi Lab Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
CA2222138C (en) * 1995-05-25 2008-10-14 G.D. Searle & Co. Method of preparing 3-haloalkyl-1h-pyrazoles
DE69620136T2 (de) * 1995-06-06 2002-08-01 Bayer Ag Antibakterielle präparate für die ohren ohne irritierende, sensibilisierende und ototoxische wirkungen
US5756529A (en) * 1995-09-29 1998-05-26 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
AP9700912A0 (en) * 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
ES2311571T3 (es) * 1996-04-12 2009-02-16 G.D. Searle Llc Derivados de bencenosulfonamida sustituidos como profarmacos de inhibidores de cox-2.
US5736151A (en) * 1996-12-09 1998-04-07 Pharmacia & Upjohn Company Antibiotic oil suspensions
US6307047B1 (en) * 1997-08-22 2001-10-23 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
US6395746B1 (en) * 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US6440964B1 (en) * 1998-09-30 2002-08-27 Alcon Manufacturing, Ltd. Compositions and methods for treating ophthalmic and otic infections
US6509327B1 (en) * 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
AR020660A1 (es) * 1998-09-30 2002-05-22 Alcon Lab Inc Composiciones antibioticas para el tratamiento de ojos, oidos y nariz
US7064132B2 (en) * 1999-11-28 2006-06-20 Scientific Development And Research, Inc. Composition and method for treatment of otitis external
US6676930B2 (en) * 1999-11-28 2004-01-13 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
AP2002002582A0 (en) * 1999-12-23 2002-09-30 Nitromed Inc Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
US20010049366A1 (en) * 2000-02-09 2001-12-06 Alcon Universal Ltd. Topical solution formulations containing an antibiotic and a corticosteroid
AU2001251011A1 (en) * 2000-03-27 2001-10-08 The General Hospital Corporation Treatments for immune-mediated ear disorders
EP2329842A3 (en) * 2000-05-12 2011-07-27 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
AU2001274858A1 (en) * 2000-06-08 2001-12-17 Board Of Regents, The University Of Texas System Heterocycle derivatives and methods of use for treating anthrax infection
CA2410632A1 (en) * 2000-06-22 2001-12-27 David S. Garvey Nitrosated and nitrosylated taxanes, compositions and methods of use
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions

Also Published As

Publication number Publication date
CL2004000471A1 (es) 2005-04-22
AR043651A1 (es) 2005-08-03
US20040214753A1 (en) 2004-10-28
AU2004222518A1 (en) 2004-09-30
CA2519589A1 (en) 2004-09-30
NZ541780A (en) 2008-06-30
ZA200506531B (en) 2006-11-29
KR20050114245A (ko) 2005-12-05
WO2004082719A1 (en) 2004-09-30
RU2005126363A (ru) 2006-05-10
KR100765614B1 (ko) 2007-10-09
CN1761486A (zh) 2006-04-19
NO20054777L (no) 2005-10-17
CO5611165A2 (es) 2006-02-28
TW200507852A (en) 2005-03-01
JP2006520778A (ja) 2006-09-14
EP1608406A1 (en) 2005-12-28
MXPA05010019A (es) 2005-11-17
RU2321423C2 (ru) 2008-04-10
BRPI0408559A (pt) 2006-03-21
UY28236A1 (es) 2004-11-08

Similar Documents

Publication Publication Date Title
TWI265809B (en) Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
TW200503756A (en) Dispersible formulation of an anti-inflammatory agent
TW200420299A (en) Dispersible pharmaceutical compositions
WO2002041883A3 (en) As-needed administration of tricyclic and other non-sri antidepressant drugs to treat premature ejaculation
WO2005009436A8 (en) Dispersible formulation of an anti-inflammatory agent
HUP0401344A2 (hu) Gyógyszerkészítmények opioidokkal való visszaélés megakadályozására, és eljárás előállításukra
RS51961B (en) APPLICATION OF FLIBANSERINE FOR TREATMENT OF SEXUAL DESIRE DISORDERS IN PREMENOPAUSE
NO20031019D0 (no) Vedvarende frigivelsesformuleringer av oksymorfon
WO2004071529A3 (en) Uses of anti-insulin-like growth factor i receptor antibodies
WO2002085248A3 (en) Prostanoids augment ocular drug penetration
CA2363990A1 (en) Use of glycyrrhizin in the treatment of mastitis
WO2005007112A3 (en) Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
ATE299740T1 (de) Kombination aus einem no-donor und einem antioxidans zur behanndlung sexueller störungen
US5888523A (en) Topical non-steroidal anti-inflammatory drug composition
AU2003301747A8 (en) Pharmaceutical compositions suitable for the treatment of ophthalmic diseases
PL362803A1 (en) Novel method and compositions for local treatment of meniere's disease, tinnitus and/or hearing loss
EP2506841A1 (en) Topical use of hydroxytyrosol and derivatives for the prevention of hiv infection
WO2002051379A3 (en) Thixotropic nasal spray
RU2372933C1 (ru) Лекарственное средство и лекарственная композиция для его изготовления
CA2515259A1 (en) Use of acetylsalicylic acid for the treatment of hemorrhoidal disease
WO2005009472A3 (en) Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
SE9700617D0 (sv) New composition
RU2002104662A (ru) Способ профилактики послеродового эндометрита у коров
CN1435264A (zh) 阴茎式给药套
BG104894U (en) Antitussive means

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees